Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics.

Njabulo Mnyandu, Shonisani Wendy Limani, Patrick Arbuthnot, Mohube Betty Maepa

Virology journal 2021 Dec 13

filter terms:

Despite the five decades having passed since discovery of the hepatitis B virus (HBV), together with development of an effective anti-HBV vaccine, infection with the virus remains a serious public health problem and results in nearly 900,000 annual deaths worldwide. Current therapies do not eliminate the virus and viral replication typically reactivates after treatment withdrawal. Hence, current endeavours are aimed at developing novel therapies to achieve a functional cure. Nucleic acid-based therapeutic approaches are promising, with several candidates showing excellent potencies in preclinical and early stages of clinical development. However, this class of therapeutics is yet to become part of standard anti-HBV treatment regimens. Obstacles delaying development of gene-based therapies include lack of clinically relevant delivery methods and a paucity of good animal models for preclinical characterisation. Recent studies have demonstrated safety and efficiency of Adeno-associated viral vectors (AAVs) in gene therapy. However, AAVs do have flaws and this has prompted research aimed at improving design of novel and artificially synthesised AAVs. Main goals are to improve liver transduction efficiencies and avoiding immune clearance. Application of AAVs to model HBV replication in vivo is also useful for characterising anti-HBV gene therapeutics. This review summarises recent advances in AAV engineering and their contributions to progress with anti-HBV gene therapy development. © 2021. The Author(s).

Citation

Njabulo Mnyandu, Shonisani Wendy Limani, Patrick Arbuthnot, Mohube Betty Maepa. Advances in designing Adeno-associated viral vectors for development of anti-HBV gene therapeutics. Virology journal. 2021 Dec 13;18(1):247